The Rabies Diagnostics Market is expected to reach USD 1713.09 Million by 2030 at 3.90% CAGR during the forecast period 2022-2030.Rabies spread through an animal bite or saliva with symptoms like fever, muscle spasms, excess salivation, headache, and mental instability. The common rabies diagnostic methods include the Fluorescent Antibody Test (FAT), Direct Fluorescent Antibody (DFA) test, immunohistochemical tests, and amplification methods. The key market driving factor is the rise in awareness and concern for animal-related diseases. The growing awareness programs initiated by the government to fight against rabies and the growing necessity of immunization for humans and animals are enhancing the market. The surveillance strategies and development of rabies diagnostics kits contribute to the market's growth. Major initiatives such as dog vaccinations, post-exposure prophylaxis (PEP) adoption, and the government's involvement in the laws regarding the diagnosis of rabies virus are aiding the market's growth. The rabies diagnostics market is accelerated by the rise in the adoption of advanced diagnostic solutions for rabies, the collaborations between research institutes and healthcare companies, novel rabies detection assays and kit development, and the initiatives organizations undertake to control the spread of rabies are factors propelling the market. The adoption of cutting-edge technologies for rabies diagnostic solutions is influencing more demand. On the other hand, the investments to support ongoing research activities and the invention of rabies diagnosis kits will increase the market's growth opportunities. The key player’s developments will boost the market.
Rabies Diagnostics Market Segmentation
The global rabies diagnostics market has been segmented on the basis of method, technology, end-user, and region.
On the basis of method, the market has been classified as a fluorescent antibody test (FAT), immunohistochemical test, amplification methods, histologic examination, and serology tests. Also, by technology, the market has been segmented into ELISA/immunohistochemistry, chromatography techniques, PCR, and others.
Based on market has been divided into hospitals, diagnostic centers, cancer palliative care clinics, and others. By end-user hospitals are likely to register the highest CAGR owing to the rising prevalence of rabies in emerging countries during the forecast period.
The market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The rabies diagnostics market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada.
The European rabies diagnostics market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe.
The market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The market in the Middle East & Africa has been segmented into the Middle East and Africa.
Rabies Diagnostics Regional Market Summary
Global Rabies Diagnostics Market Share, by Region, 2017 (%)
Source: MRFR Analysis
Asia-Pacific is likely to dominate the rabies diagnostics market during the forecast period owing to the improving healthcare infrastructure, rising investments in healthcare and expansions by market players in the region. Also, countries such as India and China are considering the fastest growing region due to a government focused toward adopting new technology and the best treatment option from a developed country. According to the World Health Organization, in 2010, the healthcare expenditure of India was 3.27% of GDP, whereas, in 2015 it has 3.89% of total GDP.
The Americas are likely to be the second-largest market in the global rabies diagnostics market owing to the rising strategic alliance by major players, increasing awareness about rabies, the involvement of non-profit organization to control rabies, and well-established healthcare infrastructure. According to the American Pet Products Association's 2017-2018 National Pet Owners Survey, Number of animals in the American region is increasing, and there were around 60.2 million dogs, and47.1pet cats were present in the Americas.
The European market is expected to hold a significant share in the rabies diagnostics market. The market growth in this region can be attributed to the government funding, well-established healthcare sector, and support of the healthcare sector coupled with increasing research and development.
The market in the Middle East & Africa is expected to account for the smallest share of the global rabies diagnostics market due to an underdeveloped healthcare sector, lack of technical knowledge, and poor medical facilities.
Rabies Diagnostics Market Key Players
Some of the key players in the global market are Bio-Rad Laboratories, Inc., Merck KGaA, Aviva Systems Biology Corporation, Creative Diagnostics, Demeditec Diagnostics GmbH, Abbexa Ltd., Norgen Biotek Corp., BioNote, Inc., Express Biotech International Inc., MyBioSource.com., and BioGen Technologies
Global Rabies Diagnostics Market, by Method
- Fluorescent Antibody Test (FAT)
- Immunohistochemical Test
- Amplification Methods
- Histologic Examination
- Serology Tests
Global Rabies Diagnostics Market, by Technology
- Chromatography Techniques
Global Rabies Diagnostics Market, by End User
- Diagnostic centers
- Cancer Palliative care clinics
Global Rabies Diagnostics Market, by Region
- North America
- Latin America
- Western Europe
- Rest of Western Europe
- Eastern Europe
- South Korea
- Rest of Asia-Pacific
- Bio-Rad Laboratories, Inc.
- Merck KGaA
- Aviva Systems Biology Corporation
- Creative Diagnostics
- Demeditec Diagnostics GmbH
- Abbexa Ltd.
- Norgen Biotek Corp.
- BioNote, Inc.
- Express Biotech International Inc.
- BioGen Technologies
In April 2022
Cadila Pharmaceuticals announced that it had developed the world's first novel three-dose vaccine against rabies. The three-dose vaccine, named 'ThRabis,' is a recombinant nano-particle-based G protein vaccine prepared using Virus-like Particle technology.
The company added that the three-dose schedule is spread over one week.
The new vaccine will prove to be a game-changer because all the other rabies vaccines require five injections over 28 days to eliminate the threatCadila, Pharmaceuticals said at the launch ceremony of the new vaccine.
- Rabies Diagnostics Manufacturers
- Rabies Diagnostics Distributors and Suppliers
- Healthcare Providers
- Research Institutes and Academic Centers
- Medical Devices Manufacturers
- Government Associations
- Market Research and Consulting